SXTP
60 Degrees Pharmaceuticals, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-35/100
Last price
1.00
▼ 0.44 (30.53%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.99
Prev close
1.44
Day high
1.20
Day low
0.89
Volume
2.45M
Market cap
$3.90M
P/E (TTM)
—
52W range
0.84 – 8.62
Day trading desk
Gap from prior close
-31.25%
Prior close 1.44
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
2.02%
0.99 – 1.01
Position in range
51%
Mid range
ATR (14D)
0.17
16.85% of price
Prior day high
1.66
PDH
Prior day low
1.36
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 99.97K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-11.20%
-13.1%
1M
+20.78%
+19.6%
3M
-28.39%
-32.9%
6M
-37.29%
-55.5%
YTD
-45.37%
-59.6%
1Y
-80.46%
-96.9%
3Y
-99.38%
-181.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SXTP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
681.98K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 12, 26 | DOW GEOFFREY S Chief Executive Officer |
BUY | 7.35K | $10.13K | Direct |
| Dec 15, 25 | DOW GEOFFREY S Chief Executive Officer |
BUY | 9.67K | $7.76K | Direct |
| Dec 11, 25 | DOW GEOFFREY S Chief Executive Officer |
BUY | 12.96K | $12.20K | Direct |
| Sep 12, 25 | DOW GEOFFREY S Chief Executive Officer |
STOCK | 7.20K | $10.00K | Direct |
| Jun 9, 25 | DOW GEOFFREY S Chief Executive Officer |
STOCK | 4.38K | $13.06K | Direct |
| Jun 3, 25 | XU CHERYL Director |
BUY | 5.00K | $14.41K | Direct |
| Jan 17, 25 | DOW GEOFFREY S Chief Executive Officer |
— | 14.39K | — | Direct |
| Jan 17, 25 | MILLER TYRONE Chief Financial Officer |
— | 11.63K | — | Direct |
| Jan 17, 25 | LANDON KRISTEN Chief Operating Officer |
— | 4.54K | — | Direct |
| Dec 16, 24 | XU CHERYL Director |
BUY | 13.00K | $21.40K | Direct |
| Dec 9, 24 | DOW GEOFFREY S Chief Executive Officer |
BUY | 73.95K | $89.75K | Direct |
| Nov 21, 24 | DOW GEOFFREY S Chief Executive Officer |
BUY | 7.00K | $6.37K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DOW GEOFFREY S |
Chief Executive Officer | 24.13K | Purchase |
LANDON KRISTEN |
Chief Operating Officer | 4.54K | Stock Award(Grant) |
MILLER TYRONE |
Chief Financial Officer | 26.37K | Stock Award(Grant) |
XU CHERYL |
Director | 15.82K | Purchase |
Fundamentals
Market cap$3.90M
Enterprise value$12.51M
Revenue (TTM)$1.21M
Gross profit$-2.06M
EBITDA$-8.50M
Net income$-8.62M
EPS (TTM)$-5.34
Free cash flow$-6.08M
Total cash$1.02M
Total debt$151.18K
Book value / share$-2.62
Shares outstanding3.52M
Float2.44M
Short % of float6.18%
Dividend yield0.00%
Beta (5Y)2.40
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.31
PEG ratio—
Price / sales—
Price / book—
EV / revenue10.30
EV / EBITDA-1.47
Gross margin-169.87%
Operating margin-1092.41%
Profit margin0.00%
Return on equity-332.85%
Return on assets-127.11%
Debt / equity5.98
Current ratio2.33
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.01M | $607.57K | $253.57K | $223.21K | +65.5% |
| Operating revenue | $1.01M | $607.57K | $253.57K | $223.21K | +65.5% |
| Cost of revenue | $781.70K | $384.76K | $474.55K | $432.37K | +103.2% |
| Gross profit | $223.78K | $222.81K | -$220.98K | -$209.16K | +0.4% |
| Research & development | $2.11M | $4.99M | $691.77K | $525.56K | -57.8% |
| Selling, general & admin | $6.28M | $5.03M | $4.24M | $1.30M | +25.0% |
| Total operating expense | $7.98M | $9.94M | $4.93M | $1.54M | -19.7% |
| Operating income | -$7.76M | -$9.72M | -$5.15M | -$1.75M | +20.1% |
| Net interest income | -$7.80K | -$7.91K | -$2.29M | -$3.99M | +1.4% |
| Pre-tax income | -$7.37M | -$7.96M | -$3.81M | -$6.18M | +7.4% |
| Tax provision | $0 | $0 | $250 | $500 | — |
| Net income | -$7.37M | -$7.95M | -$3.77M | -$6.18M | +7.3% |
| Net income to common | -$7.37M | -$7.95M | -$3.77M | -$6.18M | +7.3% |
| Basic EPS | -11.73 | -74.17 | -236.72 | -266.38 | +84.2% |
| Diluted EPS | -11.73 | -74.17 | -236.72 | -266.38 | +84.2% |
| EBIT | -$7.36M | -$7.95M | -$1.53M | -$2.19M | +7.4% |
| EBITDA | -$7.28M | -$7.88M | -$1.43M | -$2.11M | +7.7% |
| Basic shares | 670.21K | 113.67K | 16.58K | 23.21K | +489.6% |
| Diluted shares | 670.21K | 113.67K | 16.58K | 23.21K | +489.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.51M | $1.66M | $2.14M | $264.87K | -9.0% |
| Cash & short-term investments | $1.51M | $1.66M | $2.14M | $264.87K | -9.0% |
| Accounts receivable | $509.64K | $486.75K | $231.33K | $45.97K | +4.7% |
| Inventory | $656.92K | $442.76K | $466.17K | $518.58K | +48.4% |
| Total current assets | $4.90M | $5.39M | $7.24M | $1.10M | -9.1% |
| Property, plant & equipment | $246.37K | $149.81K | $71.28K | $33.95K | +64.5% |
| Goodwill & intangibles | $224.36K | $157.08K | $227.26K | $164.25K | +42.8% |
| Total assets | $5.37M | $5.76M | $7.78M | $1.30M | -6.8% |
| Total current liabilities | $1.84M | $1.66M | $2.84M | $23.92M | +11.2% |
| Current debt | $8.77K | $8.77K | $8.77K | $21.14M | 0.0% |
| Long-term debt | $144.00K | $147.12K | $150.25K | $1.27M | -2.1% |
| Total debt | $152.78K | $155.89K | $172.67K | $22.42M | -2.0% |
| Total liabilities | $1.99M | $1.80M | $2.99M | $25.45M | +10.1% |
| Retained earnings | -$47.89M | -$40.53M | -$32.58M | -$28.82M | -18.2% |
| Shareholder equity | $3.46M | $4.04M | $4.87M | -$23.58M | -14.2% |
| Working capital | $3.05M | $3.73M | $4.41M | -$22.82M | -18.1% |
| Net tangible assets | $3.24M | $3.88M | $4.64M | -$23.74M | -16.5% |
| Shares issued | 1.16M | 141.73K | 24.21K | 23.21K | +720.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$7.37M | -$7.96M | -$3.81M | -$6.18M | +7.4% |
| Depreciation & amortisation | $82.87K | $63.74K | $100.37K | $78.79K | +30.0% |
| Stock-based compensation | $456.34K | $3.61M | $1.74M | $0 | -87.4% |
| Change in working capital | -$5.50K | $192.72K | $405.36K | $3.37M | -102.9% |
| Operating cash flow | -$6.85M | -$5.65M | -$4.54M | -$1.01M | -21.3% |
| Capital expenditure | -$218.08K | -$181.11K | -$115.89K | -$60.13K | -20.4% |
| Investing cash flow | $254.92K | -$1.89M | -$115.89K | -$60.13K | +113.5% |
| Financing cash flow | $6.44M | $7.05M | $6.47M | $1.22M | -8.7% |
| Free cash flow | -$7.07M | -$5.83M | -$4.66M | -$1.07M | -21.2% |
| End cash position | $1.51M | $1.66M | $2.14M | $264.87K | -9.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $207.90K | $162.09K | $303.38K | $437.60K | $100.93K | — | +28.3% |
| Operating revenue | $207.90K | $162.09K | $303.38K | $437.60K | $100.93K | — | +28.3% |
| Cost of revenue | $151.10K | $85.72K | $120.68K | $537.69K | $50.05K | — | +76.3% |
| Gross profit | $56.80K | $76.38K | $182.70K | -$100.09K | $50.88K | — | -25.6% |
| Research & development | $598.65K | $281.46K | $638.87K | $809.78K | $231.91K | — | +112.7% |
| Selling, general & admin | $1.73M | $1.89M | $1.47M | $1.51M | $1.63M | — | -8.5% |
| Total operating expense | $2.33M | $2.17M | $2.10M | $2.23M | $1.66M | — | +7.2% |
| Operating income | -$2.27M | -$2.09M | -$1.92M | -$2.33M | -$1.61M | — | -8.4% |
| Net interest income | -$1.40K | -$1.39K | -$3.09K | -$1.71K | -$1.22K | — | -1.0% |
| Pre-tax income | -$2.27M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | — | -8.4% |
| Tax provision | $0 | $0 | -$1.81K | $250 | $0 | — | — |
| Net income | -$2.26M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | — | -8.4% |
| Net income to common | -$2.26M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | — | -8.4% |
| Basic EPS | -0.90 | -1.28 | — | -2.52 | -5.01 | -6.25 | +29.7% |
| Diluted EPS | -0.90 | -1.28 | — | -2.52 | -5.01 | -6.25 | +29.7% |
| EBIT | -$2.26M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | — | -8.4% |
| EBITDA | -$2.23M | -$2.06M | -$1.41M | -$2.29M | -$1.71M | — | -8.3% |
| Basic shares | 2.65M | 1.73M | — | 918.85K | 368.25K | 320.89K | +53.8% |
| Diluted shares | 2.65M | 1.73M | — | 918.85K | 368.25K | 320.89K | +53.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.02M | $3.34M | $1.51M | $4.12M | $1.97M | -69.4% |
| Cash & short-term investments | $1.02M | $3.34M | $1.51M | $4.12M | $1.97M | -69.4% |
| Accounts receivable | $567.04K | $335.84K | $509.64K | $674.04K | $295.03K | +68.8% |
| Inventory | $877.95K | $910.60K | $656.92K | $527.00K | $799.42K | -3.6% |
| Total current assets | $3.73M | $6.26M | $4.90M | $6.31M | $3.84M | -40.4% |
| Property, plant & equipment | $242.71K | $259.67K | $246.37K | $227.75K | $193.88K | -6.5% |
| Goodwill & intangibles | $308.68K | $243.21K | $224.36K | $152.38K | $143.70K | +26.9% |
| Total assets | $4.28M | $6.76M | $5.37M | $6.69M | $4.18M | -36.7% |
| Total current liabilities | $1.61M | $1.88M | $1.84M | $2.20M | $1.69M | -14.4% |
| Current debt | $2.00K | $8.77K | $8.77K | $8.77K | $8.77K | -77.2% |
| Long-term debt | $149.18K | $143.20K | $144.00K | $144.99K | $145.48K | +4.2% |
| Total debt | $151.18K | $151.97K | $152.78K | $153.76K | $154.25K | -0.5% |
| Total liabilities | $1.75M | $2.02M | $1.99M | $2.34M | $1.84M | -13.1% |
| Retained earnings | -$52.25M | -$49.98M | -$47.89M | -$46.45M | -$44.14M | -4.5% |
| Shareholder equity | $2.61M | $4.83M | $3.46M | $4.43M | $2.43M | -45.9% |
| Working capital | $2.13M | $4.38M | $3.05M | $4.11M | $2.15M | -51.5% |
| Net tangible assets | $2.31M | $4.59M | $3.24M | $4.28M | $2.28M | -49.7% |
| Shares issued | 2.66M | 2.64M | 1.16M | 1.03M | 368.22K | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.27M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | -8.4% |
| Depreciation & amortisation | $30.81K | $25.86K | $23.57K | $22.83K | $19.68K | +19.1% |
| Stock-based compensation | $2.40K | $124.10K | $111.96K | $167.24K | -$9.62K | -98.1% |
| Change in working capital | -$101.02K | -$554.26K | $26.61K | -$159.65K | $46.06K | +81.8% |
| Operating cash flow | -$2.23M | -$2.74M | -$1.69M | -$2.11M | -$1.45M | +18.6% |
| Capital expenditure | -$85.98K | -$41.44K | -$135.43K | -$25.49K | -$51.68K | -107.5% |
| Investing cash flow | -$85.98K | $1.19M | -$1.37M | -$25.49K | -$51.68K | -107.2% |
| Financing cash flow | $0 | $3.37M | $458.61K | $4.28M | $0 | -100.0% |
| Free cash flow | -$2.32M | -$2.78M | -$1.83M | -$2.13M | -$1.50M | +16.7% |
| End cash position | $1.02M | $3.34M | $1.51M | $4.12M | $1.97M | -69.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.89 | -0.86 | +3.8% |
| Mar 2026 | -0.99 | -1.21 | -22.6% |
| Dec 2025 | -2.00 | -8.17 | -308.6% |
| Sep 2025 | -1.84 | -2.53 | -37.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.85 | 1 | $270.00K | -48.9% |
| Next quarter | -0.89 | 1 | $310.00K | +2.2% |
| Current year | -3.45 | 1 | $1.00M | -0.5% |
| Next year | -3.58 | 1 | $1.70M | +70.0% |
Analyst targets & ownership
Mean target$3.70
High target$3.70
Low target$3.70
Implied upside269.89%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders19.39%
Held by institutions17.11%
Institutions holding12
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.25
-19.98% from price
SMA 20
1.10
+1.19% from price
SMA 50
1.12
-0.61% from price
SMA 100
1.32
-24.35% from price
SMA 200
1.91
-41.77% from price
EMA 12
1.21
-17.47% from price
EMA 26
1.15
-13.17% from price
EMA 50
1.18
-15.51% from price
RSI (14)
47.8
Neutral
MACD (12,26,9)
0.06
Hist 0.03
ATR (14)
0.17
15.19% of price
Realised vol 30D
112.0%
Annualised
Bollinger upper
1.44
20, 2σ
Bollinger lower
0.75
20, 2σ
50 / 200 cross
Death
1.12 vs 1.91
Trend bias
Below 200
-41.77%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.11
More volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
112.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-88.2%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.17
15.19% of price
Beta (reported)
2.40
5Y monthly, from filing
Short interest
Shares short
215.99K
Prior 277.18K
Change vs prior
-22.1%
Shorts covering
% of float
6.18%
Normal
% of shares out
6.14%
Against total outstanding
Days to cover
3.7
Liquid
Float
2.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 22, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| May 20, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 9, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jan 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 28, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Sep 3, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 2, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Mar 28, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Feb 25, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jan 10, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Dec 23, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Dec 11, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:4
Split dateJan 20, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-08
Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement
DEL AM · 2026-08-17
Offering Registrations
S-3 · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-20
Headlines
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
InvestorsHub · 18h ago
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
GlobeNewswire · 20h ago
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESS Newswire · 5d ago
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
GlobeNewswire · 6d ago
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 34d ago
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
GlobeNewswire · 54d ago
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 57d ago
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Zacks · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.